ObsEva with a positive start at Swiss Exchange

From today on ObsEva’s shares are listed and trade under the “International Reporting Standard” on SIX Swiss Exchange. The issued share capital comprises 45‘381‘252 registered shares with a nominal value of 1/13 of CHF 1 each. ObsEva will not issue any new shares in connection with the listing in Switzerland. ObsEva is listed on The NASDAQ Global Select Market since January 2017.   

Ernest Loumaye, CEO and Co-Founder of ObsEva said: “We are proud to initiate the listing at the SIX today as it marks an important milestone for our company. The SIX Swiss Exchange is Europe's leading exchange for life sciences companies and Swiss institutional and private investors have developed a strong understanding of the healthcare sector. Our late-stage clinical pipeline offers numerous opportunities and is progressing well. Recent results demonstrate the efficacy of our therapies and confirm the potential therapeutic benefits.”

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes.

(Press release / SK)